Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$111K Sell
1,416
-54
-4% -$3.68K ﹤0.01% 997
2026
Q1
$95K Buy
1,470
+174
+13% +$12.3K ﹤0.01% 992
2025
Q4
$87.2K Buy
1,296
+200
+18% +$13.5K ﹤0.01% 1014
2025
Q3
$80.4K Buy
1,096
+101
+10% +$6.71K ﹤0.01% 963
2025
Q2
$51.8K Sell
995
-324
-25% -$18.4K ﹤0.01% 1106
2025
Q1
$84.2K Buy
1,319
+960
+267% +$55.8K ﹤0.01% 843
2024
Q4
$17.2K Sell
359
-17
-5% -$872 ﹤0.01% 1317
2024
Q3
$21.5K Buy
376
+296
+370% +$17K ﹤0.01% 1194
2024
Q2
$4.19K Buy
80
+42
+111% +$1.84K ﹤0.01% 1487
2024
Q1
$1.55K Buy
+38
New +$1.43K ﹤0.01% 1610
2023
Q1
Sell
-584
Closed -$33K 1740
2022
Q4
$33K Hold
584
﹤0.01% 959
2022
Q3
$23K Buy
+584
New +$25.8K ﹤0.01% 1062

Other funds holding HALO

UMB Bank's HALO Position: Q2 2026 in Review

UMB Bank reduced its Halozyme (HALO) stake by 3.7% in Q2 2026, selling an estimated $3.68K and leaving 1,416 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #997.

UMB Bank first reported a position in HALO in Q3 2022 and has held it in 12 quarters since. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • UMB Bank held 1,416 shares of Halozyme worth $111K as of Q2 2026.
  • UMB Bank sold 54 Halozyme shares in Q2 2026, an estimated $3.68K.
  • Halozyme made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #997 holding.
  • UMB Bank first reported a position in Halozyme in Q3 2022 and has held it in 12 quarters since.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.